Boston Scientific Corporation logo BSX - Boston Scientific Corporation

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 1
BUY 38
HOLD 5
SELL 0
STRONG
SELL 0
| PRICE TARGET: $82.90 DETAILS
HIGH: $120.00
LOW: $55.00
MEDIAN: $76.00
CONSENSUS: $82.90
UPSIDE: 83.04%
AlphaVal

AlphaVal

Deterministic, archetype-aware fair value

Platform & Compounding FCF 85% confidence

Primary model: Two-stage FCF DCF

Valuation Signal Undervalued Moderate
Trading 34.0% below fair value
Current Price $45.29
Bear Case $41.84 7.6% downside ($41.84 - $45.29) / $45.29 = -7.6% 9% stage 1 growth, 11% discount
Fair Value $68.65 51.6% upside ($68.65 - $45.29) / $45.29 = 51.6% 14% stage 1 growth, 11% discount
Bull Case $98.10 116.6% upside ($98.10 - $45.29) / $45.29 = 116.6% 19% stage 1 growth, 11% discount

Adjust Assumptions

14.4%
11.0%
3.0%

Key Value Driver

FCF growth rate (14% base case)

Terminal Value % of EV 42%
Implied Market Multiple 22.6x

Plain-Language Summary

Our base-case estimate uses a two-stage discounted cash flow model based on free cash flow. We then blend that result with the average analyst price target of $82.90 from 44 analysts, using a 30% weight on analyst consensus. That produces an estimated intrinsic value of $68.65 per share.

Key Risks

  • P/E alone misleads — earnings depressed by growth investment
  • Cyclical or commodity businesses may be misclassified as platforms
  • Terminal value dominance suggests sensitivity to long-run assumptions